Samira Hassanzadeh, - Department of Optometry, Student Research Committee, Mashhad University of Medical Sciences,Mashhad, Iran
Akbar Derakhshan, - Department of Optometry, Student Research Committee, Mashhad University of Medical Sciences,Mashhad, Iran
Alireza Eslampour - Department of Optometry, Student Research Committee, Mashhad University of Medical Sciences,Mashhad, Iran
Esmaeil Safinezhad - Department of Optometry, Student Research Committee, Mashhad University of Medical Sciences,Mashhad, Iran

Purpose: Bevacizumab (Avastin), as an effectiveness treatment modality, is currently used in patients with various ocular disease. However the results have been promising, the use of bevacizumab in the treatment of ocular disease is an off-label application. Hence, the aim of this study was to systematically review the effectiveness of intravitreal injection of bevacizumab on various ocular tissues, especially corneal endothelial cells. Methods: The articles related to the effect of application of Avastin in the treatment of ophthalmic diseases and especially its effect on corneal endothelial cells were collected and reviewed. We searched PubMed, Google scholar, and Scopus databases and used Avastin, ocular diseases and corneal endothelial cells as search keywords. Results: Of all 55 articles found in all databases, only 10 were relevant to the purpose of this study, and 45 articles were excluded in several step by step process of article selection according to the inclusion/exclusion criteria. The results revealed that intracameral bevacizumab injection caused no changes in specular microscopy and corneal pachymetry. Moreover, it had no significant toxicity on corneal endothelial cells. Conclusion: According to the results of included documents, bevacizumab was not toxic to corneal endothelial cells at various clinically relevant doses.